Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.60 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16672732 | 0.92 | CYP4F2 (0.57) | CYP4F2CYP4A11EPHX2ALDH1A1PPARG | |
| SCHEMBL16672593 | 0.91 | CYP4F2 (0.63) | CYP4F2CYP4A11EPHX2ALDH1A1PPARG | |
| SCHEMBL6343659 | 0.85 | PPARG (0.48) | CYP4F2CYP4A11EPHX2PPARGAPP | |
| SCHEMBL7687145 | 0.82 | CYP4F2 (0.67) | CYP4F2CYP4A11ALDH1A1GAAPOLB | |
| SCHEMBL16673226 | 0.82 | CYP4F2 (0.67) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL27624240 | 0.82 | VNN1 (0.46) | EPHX2GAAPPARGDRD2SLC6A3 | |
| SCHEMBL30670216 | 0.81 | CYP4F2 (0.61) | CYP4F2CYP4A11EPHX2ALDH1A1GAA | |
| SCHEMBL69660 | 0.81 | CYP4F2 (0.86) | CYP4F2CYP4A11EPHX2ALDH1A1GAA | |
| SCHEMBL30055829 | 0.80 | FFAR1 (0.56) | PPARGDRD2SLC6A3 | |
| SCHEMBL1508357 | 0.80 | FFAR1 (0.56) | PPARGDRD2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-1996012697-A9 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMA INC (US) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | CYP4F2 1213/4885CYP4A11 2315/4885EPHX2 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.